| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.22 | 5e-09 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.21 | 1e-07 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-07 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.19 | 3e-07 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-07 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.25 | 2e-06 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |